Malignant Tumor Of Ovary — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for malignant tumor of ovary. 45 active patents protecting 4 drugs from 4+ originators. First major cliff: 2028. Daily refresh.

4
Approved drugs
45
Active US patents
57/100
Avg vulnerability
$2.6B
Annual revenue covered

Originators in Malignant Tumor Of Ovary

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

AstraZeneca 25 patents Accord Hlthcare 15 patents MYLAN SEIYAKU Ltd 3 patents Janssen Prods 2 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating malignant tumor of ovary. Each bar = one year. Y-axis scaled to peak year (12 patents).

7
27
3
28
12
29
2
30
3
31
1
32
10
33
2
34

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Lynparza
olaparib
 AstraZeneca 25 59 $2.6B 2027-08-12
Gemzar
Gemcitabine Hydrochloride
 Accord Hlthcare 15 48 — 2030-06-28
Paraplatin
Carboplatin
 MYLAN SEIYAKU Ltd 3 55 — 2045-04-01
Yondelis
TRABECTEDIN
 Janssen Prods 2 65 — 2028-01-07

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
8071579 Lynparza method of use 75 2027-08-12
8143241 Lynparza method of use 75 2027-08-12
8071579 Lynparza method of use 75 2027-08-12
8143241 Lynparza method of use 75 2027-08-12
8143241 Lynparza method of use 75 2027-08-12
8895557 Yondelis other 75 2028-07-07
11970530 Lynparza method of use 75 2041-10-25
11970530 Lynparza method of use 75 2041-10-25
8859562 Lynparza method of use 68 2031-08-04
8859562 Lynparza method of use 68 2031-08-04

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
8247416 Lynparza composition of matter 17 2028-09-24
7449464 Lynparza composition of matter 17 2027-09-08
7449464 Lynparza composition of matter 17 2027-09-08
9241948 Gemzar formulation 42 2033-07-01
9241948 Gemzar formulation 42 2033-07-01
9241948 Gemzar formulation 42 2033-07-01
9241948 Gemzar formulation 42 2033-07-01
9241948 Gemzar formulation 42 2033-07-01
9241948 Gemzar formulation 42 2033-07-01
9241948 Gemzar formulation 42 2033-07-01

Related